ENVB — Enveric Biosciences Income Statement
0.000.00%
Last trade - 00:00- $3.19m
- $0.95m
Annual income statement for Enveric Biosciences, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Total Revenue | 0 | 0 | 0 | 0 | 0 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Depreciation and Amortization | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 5.62 | 64.6 | 27.4 | 16.4 | 9.63 |
| Operating Profit | -5.62 | -64.6 | -27.4 | -16.4 | -9.63 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -6.86 | -56.4 | -20 | -17.3 | -9.57 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -6.86 | -49 | -18.5 | -17.3 | -9.57 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -6.86 | -49 | -18.5 | -17.3 | -9.57 |
| Adjustments to Net Income | |||||
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -6.86 | -49 | -18.8 | -17.5 | -9.57 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -895 | -743 | -145 | -121 | -19 |